Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017248814> ?p ?o ?g. }
- W2017248814 endingPage "80" @default.
- W2017248814 startingPage "72" @default.
- W2017248814 abstract "The cerebral formation and entrapment of neurotoxic dicarboxylic metabolites (glutaryl-CoA, glutaric and 3-hydroxyglutaric acid) are considered to be important pathomechanisms of striatal injury in glutaric aciduria type I (GA-I). The quantitatively most important precursor of these metabolites is lysine. Recommended therapeutic interventions aim to reduce lysine oxidation (low lysine diet, emergency treatment to minimize catabolism) and to enhance physiologic detoxification of glutaryl-CoA via formation of glutarylcarnitine (carnitine supplementation). It has been recently shown in Gcdh−/− mice that cerebral lysine influx and oxidation can be modulated by arginine which competes with lysine for transport at the blood–brain barrier and the inner mitochondrial membrane [Sauer et al., Brain 134 (2011) 157–170]. Furthermore, short-term outcome of 12 children receiving arginine-fortified diet showed very promising results [Strauss et al., Mol. Genet. Metab. 104 (2011) 93–106]. Since lysine-free, arginine-fortified amino acid supplements (AAS) are commercially available and used in Germany for more than a decade, we evaluated the effect of arginine supplementation in a cohort of 34 neonatally diagnosed GA-I patients (median age, 7.43 years; cumulative follow-up period, 221.6 patient years) who received metabolic treatment according to a published guideline [Kölker et al., J. Inherit. Metab. Dis. 30 (2007) 5–22]. Patients used one of two AAS product lines during the first year of life, resulting in differences in arginine consumption [group 1 (Milupa Metabolics): mean = 111 mg arginine/kg; group 2 (Nutricia): mean = 145 mg arginine/kg; p < 0.001]. However, in both groups the daily arginine intake was increased (mean, 137 mg/kg body weight) and the dietary lysine-to-arginine ratio was decreased (mean, 0.7) compared to infants receiving human milk and other natural foods only. All other dietary parameters were in the same range. Despite significantly different arginine intake, the plasma lysine-to-arginine ratio did not differ in both groups. Frequency of dystonia was low (group 1: 12.5%; group 2: 8%) compared with patients not being treated according to the guideline, and gross motor development was similar in both groups. In conclusion, the development of complementary dietary strategies exploiting transport competition between lysine and arginine for treatment of GA-I seems promising. More work is required to understand neuroprotective mechanisms of arginine, to develop dietary recommendations for arginine and to evaluate the usefulness of plasma monitoring for lysine and arginine levels as predictors of cerebral lysine influx." @default.
- W2017248814 created "2016-06-24" @default.
- W2017248814 creator A5000052545 @default.
- W2017248814 creator A5008968351 @default.
- W2017248814 creator A5013853357 @default.
- W2017248814 creator A5015584558 @default.
- W2017248814 creator A5031080887 @default.
- W2017248814 creator A5032010875 @default.
- W2017248814 creator A5039733240 @default.
- W2017248814 creator A5039938217 @default.
- W2017248814 creator A5045218892 @default.
- W2017248814 creator A5051038361 @default.
- W2017248814 creator A5073283699 @default.
- W2017248814 creator A5089541559 @default.
- W2017248814 creator A5090027115 @default.
- W2017248814 date "2012-09-01" @default.
- W2017248814 modified "2023-09-26" @default.
- W2017248814 title "Complementary dietary treatment using lysine-free, arginine-fortified amino acid supplements in glutaric aciduria type I — A decade of experience" @default.
- W2017248814 cites W1587210733 @default.
- W2017248814 cites W1591473050 @default.
- W2017248814 cites W1594510603 @default.
- W2017248814 cites W1965028702 @default.
- W2017248814 cites W1965877738 @default.
- W2017248814 cites W1966284322 @default.
- W2017248814 cites W1967199176 @default.
- W2017248814 cites W1974274736 @default.
- W2017248814 cites W1975583150 @default.
- W2017248814 cites W1976157966 @default.
- W2017248814 cites W1978210957 @default.
- W2017248814 cites W1979828424 @default.
- W2017248814 cites W1995030535 @default.
- W2017248814 cites W2000241372 @default.
- W2017248814 cites W2003930457 @default.
- W2017248814 cites W2017194081 @default.
- W2017248814 cites W2023441960 @default.
- W2017248814 cites W2026256617 @default.
- W2017248814 cites W2028607122 @default.
- W2017248814 cites W2034715059 @default.
- W2017248814 cites W2035918187 @default.
- W2017248814 cites W2038599206 @default.
- W2017248814 cites W2040910120 @default.
- W2017248814 cites W2044076357 @default.
- W2017248814 cites W2044490121 @default.
- W2017248814 cites W2045182466 @default.
- W2017248814 cites W2046505293 @default.
- W2017248814 cites W2048782144 @default.
- W2017248814 cites W2051235302 @default.
- W2017248814 cites W2060243949 @default.
- W2017248814 cites W2060324229 @default.
- W2017248814 cites W2061367597 @default.
- W2017248814 cites W2067694285 @default.
- W2017248814 cites W2068313210 @default.
- W2017248814 cites W2069631533 @default.
- W2017248814 cites W2083304827 @default.
- W2017248814 cites W2084292798 @default.
- W2017248814 cites W2085067987 @default.
- W2017248814 cites W2089083171 @default.
- W2017248814 cites W2091766832 @default.
- W2017248814 cites W2098533067 @default.
- W2017248814 cites W2102727447 @default.
- W2017248814 cites W2103089909 @default.
- W2017248814 cites W2109920829 @default.
- W2017248814 cites W2116658403 @default.
- W2017248814 cites W2117991521 @default.
- W2017248814 cites W2120293285 @default.
- W2017248814 cites W2121524058 @default.
- W2017248814 cites W2122080454 @default.
- W2017248814 cites W2123443649 @default.
- W2017248814 cites W2127414160 @default.
- W2017248814 cites W2130639109 @default.
- W2017248814 cites W2138177495 @default.
- W2017248814 cites W2149704787 @default.
- W2017248814 cites W2150494352 @default.
- W2017248814 cites W2151270684 @default.
- W2017248814 cites W2152225659 @default.
- W2017248814 cites W2152610331 @default.
- W2017248814 cites W2159400209 @default.
- W2017248814 cites W2166477651 @default.
- W2017248814 cites W2167541052 @default.
- W2017248814 cites W2172278913 @default.
- W2017248814 cites W2331882414 @default.
- W2017248814 cites W2402265099 @default.
- W2017248814 cites W2419604885 @default.
- W2017248814 doi "https://doi.org/10.1016/j.ymgme.2012.03.021" @default.
- W2017248814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22520952" @default.
- W2017248814 hasPublicationYear "2012" @default.
- W2017248814 type Work @default.
- W2017248814 sameAs 2017248814 @default.
- W2017248814 citedByCount "43" @default.
- W2017248814 countsByYear W20172488142012 @default.
- W2017248814 countsByYear W20172488142013 @default.
- W2017248814 countsByYear W20172488142014 @default.
- W2017248814 countsByYear W20172488142015 @default.
- W2017248814 countsByYear W20172488142016 @default.
- W2017248814 countsByYear W20172488142017 @default.
- W2017248814 countsByYear W20172488142018 @default.
- W2017248814 countsByYear W20172488142019 @default.
- W2017248814 countsByYear W20172488142020 @default.